Patients receiving multiple chemotherapy including highly or moderate emetogenic agents
Conditions
Interventions
Olanzapine before the chemotherapy and on day1-5 + granisetron 1 mg i.v. on day1-5 + dexamethasone 19.8mg i.v. on day1-5
Sponsors
National cancer center hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patients receiving multiple chemotherapy ( 5days ) including highly or moderate emetogenic agent. 2) patients had never received any chemotherapy. 3) aged 15 years <=, 75> 4) Eeatern clinical oncology group performans status is 0 to 2. 5) fulfil all following conditions ANA >= 1,500/mm3 Plt >= 100,000/mm3 Hb>=9.0 g/dl T.Bil < 2.0 g/dl AST < 100 IU/L ALT < 100 IU/L Cre < 1.5 6) written informed consent from the patients
Exclusion criteria
Exclusion criteria: a)patients who had diabetes mellitus or past history of diabetes mellitus b)patients who take adrenaline beginning chemotherapy. c)patients who take barbituric acid beginning chemotherapy. d)patients who had received any chemotherapy. e)patients who take opioid. f)patients who have nausea or vomiting starting study. g)Active infectious diseases h)Severe complications i)history of hypersensitivity or allergy for study drugs or similar compounds. j)patients with clinically problematic, psycho-neurologic diseases k)pregnant, breastfeeding or expecting woman. l) patients with symptomatic brain metastasis m)patients with obstruction of gastrointestinal tract, for example ileus etc. n)patients who are disqualified by attending physicians o)patients with gastrointestinal cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| feasibility | — |
Secondary
| Measure | Time frame |
|---|---|
| To decide recommended dose. | — |
Countries
Japan
Contacts
Public ContactSeiko Bun
National cancer center hospital Pharmacy
Outcome results
None listed